Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genscript Biotech ( (HK:1548) ) just unveiled an announcement.
Genscript Biotech Corporation held its Annual General Meeting on May 29, 2025, where all proposed resolutions were passed by poll. Key decisions included the re-election of several directors and the reappointment of Ernst & Young as auditors. The meeting also granted the board mandates to issue and repurchase shares, reflecting strategic moves to enhance corporate governance and shareholder value.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation is a company incorporated in the Cayman Islands, primarily operating in the biotechnology industry. The company is involved in the development and commercialization of various biotech products and services, focusing on innovative solutions for life sciences research and applications.
Average Trading Volume: 19,110,643
Technical Sentiment Signal: Sell
Current Market Cap: HK$27.48B
See more insights into 1548 stock on TipRanks’ Stock Analysis page.